抗BCMA/GPRC5D双特异性CAR-T细胞治疗复发或难治性多发性骨髓瘤:单臂、单中心1期试验
这项单臂、单中心1期试验在复发或难治性多发性骨髓瘤患者中评估抗BCMA/GPRC5D双特异性CAR-T细胞,21例输注患者中最大耐受剂量为2.0×10^6个CAR-T细胞/kg,总缓解率86%,13例(62%)达完全缓解或更好,安全性总体可接受。
要点
- 最大耐受剂量为2.0×10^6个CAR-T细胞/kg,该剂量组总缓解率92%(11/12)。
- 21例输注患者总缓解率86%,13例(62%)完全缓解或更好,17例(81%)MRD阴性。
- 细胞因子释放综合征15例(71%)均为1-2级;4.0×10^6/kg组1例1级ICANS。
核心结论
- 抗BCMA/GPRC5D双特异性CAR-T细胞在复发或难治性多发性骨髓瘤患者中显示出良好的安全性特征和令人鼓舞的活性。
研究设计与样本
- 单臂、单中心1期试验,在徐州医科大学附属医院开展,纳入18-75岁、ECOG体能状态0-3分的复发或难治性多发性骨髓瘤患者。
- 剂量递增阶段给予0.5×10^6、1.0×10^6、2.0×10^6和4.0×10^6个CAR-T细胞/kg,并在所选剂量下增加剂量扩展阶段患者。
- 主要终点为安全性(包括剂量限制性毒性和最大耐受剂量),活性作为次要终点评估;2022年9月1日至2023年11月3日共24例入组并采集,21例输注。
- 试验注册号ClinicalTrials.gov NCT05509530,已完成。
主要发现
- 中位随访5.8个月(IQR 5.2-6.7),中位年龄62岁(IQR 56-67),男性8例(38%)、女性13例(62%),均为中国患者。
- 4.0×10^6个CAR-T细胞/kg剂量下2例发生剂量限制性毒性,其中1例死于蛛网膜下腔出血(研究治疗不认为相关);最大耐受剂量为2.0×10^6个CAR-T细胞/kg。
- 最常见3级或更严重不良事件为血液学毒性19例(90%,除淋巴细胞减少外);细胞因子释放综合征15例(71%),均为1或2级。
- 4.0×10^6个CAR-T细胞/kg组1例发生1级免疫效应细胞相关神经毒性综合征(ICANS);0.5-2.0×10^6个CAR-T细胞/kg组未观察到ICANS或3级及以上器官毒性。
- 21例输注患者总缓解率86%(18/21),13例(62%)完全缓解或更好,17例(81%)可测量残留病灶阴性;2.0×10^6个CAR-T细胞/kg组12例总缓解率92%(11/12),9例(75%)完全缓解或更好。
关键数值与推荐
- 最大耐受剂量为2.0×10^6个CAR-T细胞/kg。
- 21例输注患者总缓解率86%(18/21),完全缓解或更好13例(62%),可测量残留病灶阴性17例(81%)。
- 2.0×10^6个CAR-T细胞/kg组(12例)总缓解率92%(11/12),完全缓解或更好9例(75%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Some challenges still exist with single-target B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapies due to variable or negative BCMA expression, although they have yielded remarkable efficacy in relapsed or refractory multiple myeloma. We developed anti-BCMA/GPRC5D bispecific CARs to mitigate the limitations and potentiate the functions of CAR T cells. METHODS: This single-arm, phase 1 trial was conducted at the Affiliated Hospital of Xuzhou Medical University (Xuzhou, China). The trial enrolled patients aged 18-75 years with relapsed or refractory multiple myeloma and an Eastern Cooperative Oncology Group performance status of 0-3. Anti-BCMA/GPRC5D bispecific CAR T cells were administered at 0·5 × 106, 1·0 × 106, 2·0 × 106, and 4·0 × 106 CAR T cells per kg in the dose-escalation phase, with additional patients included at the dose selected for the dose-expansion phase. The primary endpoint was safety, which included dose-limiting toxicity and maximum tolerated dose. Activity was also evaluated as a secondary endpoint. The maximum tolerated dose was chosen for the dose-expansion phase. Safety and activity analyses were done in all patients who received anti-BCMA/GPRC5D bispecific CAR T cells as defined in the protocol. This trial is registered with ClinicalTrials.gov (NCT05509530) and is complete. FINDINGS: Between Sept 1, 2022, and Nov 3, 2023, 24 patients were enrolled and underwent apheresis. Three patients were excluded after apheresis (two patients discontinued due to rapid disease progression and one patient was withdrawn because of failed manufacture of CAR T cells), so 21 patients were infused with anti-BCMA/GPRC5D bispecific CAR T cells. Median follow-up was 5·8 months (IQR 5·2-6·7). Median age was 62 years (IQR 56-67). Eight (38%) patients were male, and 13 (62%) female. All patients were Chinese. At the 4·0 × 106 CAR T cells per kg dose, two patients had dose-limiting toxicities, of whom one died of subarachnoid haemorrhage (which was not considered to be related to the study treatment). The maximum tolerated dose was identified as 2·0 × 106 CAR T cells per kg. The most common grade 3 or worse adverse events were haematological toxicities in 19 (90%) patients (except lymphopenia). 15 (71%) patients had cytokine release syndrome, of which all cases were grade 1 or 2. One case of grade 1 immune effector cell-associated neurotoxicity syndrome (ICANS) was observed in a patient who received 4·0 × 106 CAR T cells per kg. No ICANS or grade 3 or worse organ toxicities were observed in patients who received 0·5-2·0 × 106 CAR T cells per kg. The overall response rate was 86% (18 of 21 patients), with 13 (62%) patients having a complete response or better, and 17 (81%) patients having measurable residual disease negativity. Of the 12 patients who received 2·0 × 106 CAR T cells per kg (three in the dose-escalation phase and an addition nine in the dose-expansion phase), the overall response rate was 92% (11 of 12 patients) with nine (75%) patients having a complete response or better. INTERPRETATION: Anti-BCMA/GPRC5D bispecific CAR T cells show a good safety profile and encouraging activity in patients with relapsed or refractory multiple myeloma. FUNDING: National Natural Science Foundation of China. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.
引用
- Zhou D, Sun Q, Xia J, et al. Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial. Lancet Haematol. 2024. PMID: 39059405. doi:10.1016/S2352-3026(24)00176-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。